Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 conserved regions in Gag, Pol, Vif, and Env refer to specific, highly stable amino acid sequences within the HIV-1 proteome that are critical for the virus's structural integrity and replication cycle (UniProt, 2024). These regions are functionally constrained, meaning that mutations within them typically result in a significant loss of viral fitness, making them attractive targets for therapeutic vaccines and immunotherapies (Mothe et al., 2015). By directing the host's immune system, particularly CD8+ T-cells, toward these conserved epitopes, researchers aim to circumvent the virus's ability to escape immune detection through rapid mutation (Hancock et al., 2013). This strategy is central to the development of functional cure approaches, where the goal is to achieve long-term control of the virus in the absence of antiretroviral therapy (ART). Drugs and vaccines targeting these regions, such as the HTI (HIVACAT T-cell Immunogen), are currently in clinical trials to evaluate their ability to induce broad and potent T-cell responses across different HIV-1 subtypes (IrsiCaixa, 2023; ClinicalTrials.gov, 2024).
Induction of broad, polyfunctional CD8+ and CD4+ T-cell responses targeting functionally constrained viral epitopes to prevent mutational escape and maintain viral suppression (Mothe et al., 2015; Borthwick et al., 2014).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 conserved regions in Gag, Pol, Vif, and Env (HIV-1 conserved regions).